glp-1 skincare Vol.U.Lift pending XOSM Technology For GLP-1 users dealing with

In clinical trials, patients lost an average of 2% of their body weight per month for the first six months, then 1% per month for the next six months, totaling a 16% weight loss by the end of the first year

Injection site reactionsincluding localised itching, redness, and swellingare common, affecting 110% of patients

Korner, M., Stockli, M., Waser, B

Mol Endocrinol 18:359372

Integrating genetic predisposition data with biomarker assessment (B12 status, homocysteine, liver function, carnitine) and your clinical history enables a more informed conversation with your provider about whether MIC B12, oral supplements, GLP-1 peptide therapy, or multimodal metabolic support is most appropriate for your individual situation